Table 1 Tumourigenicity of DU145 and its derivative cells.

From: α-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells

Clone

Mouse

Cell number

Tumour incidence*

Tumour volume †

Termination/measurement ‡

EV

NU/NU

5×106

4/10

28±16

38(T)

MAN2C1

NU/NU

5×106

9/10

361±112§

38(T)

Ctrl siRNA

NOD/SCID

2×105

5/5

56±6

21(M)

  

2×105

5/5

103±17

28(M)

  

2×105

5/5

165±26

35(M)

  

2×105

5/5

345±96

42(T)

PTEN siRNA

NOD/SCID

2×105

5/5

82±13

21(M)

  

2×105

5/5

127±15

28(M)

  

2×105

5/5

180±36

35(M)

  

2×105

5/5

296±72

42(T)

MAN2C1

NOD/SCID

2×105

5/5

34±3

21(M)

siRNA

 

2×105

5/5

52±1§

28(M)

  

2×105

5/5

89±11§

35(M)

  

2×105

5/5

116±13§

42(T)

PTEN/MAN2C1

NOD/SCID

2×105

5/5

78±6§

21(M)

siRNAs

 

2×105

5/5

68±9§

28(M)

  

2×105

5/5

160±15§,∥

35(M)

  

2×105

5/5

217±34§

42(T)

  1. *Number of tumours formed/number sites injected. Left and right flanks were injected for EV and MAN2C1 groups. Only left flank was implanted for the rest of groups. Five mice were used for individual groups.
  2. †Means±standard errors (mm3).
  3. ‡Termination (T, days) and measurement (M, days).
  4. §Statistical significance (<0.05) was determined by 2-tailed Student's t-test, MAN2C1 tumours versus EV tumours; MAN2C1 siRNA tumours versus the respective Ctrl siRNA tumours; PTEN/MAN2C1 siRNAs versus the corresponding MAN2C1 siRNA tumours.
  5. ∥ P=0.057.
Back to article page